Drug Approval | April 13, 2024
USFDA completes inspection of Lupin's Dabhasa facility with no observations
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
A significant proportion of healthcare professionals still tend to favor branded drugs
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
International Business is expected to register double-digit growth in constant currency terms
New leadership team announced at NATHEALTH Annual General Meeting 2024
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
